More smoking cessation programmes should be encouraged.
New and better vaccines need to be developed for high-risk groups.
The causative pathogens of pneumonia need to be determined, along with improved knowledge of the distribution and frequency of antibiotic-resistant bacteria in patients with pneumonia.
Clinical studies need to be initiated to determine the significance of antibiotic resistance.
Further randomised controlled clinical trials comparing antibiotic therapies are required.
The clinical applicability of new microbial diagnostic tools has to be evaluated.
If you would like to be kept up-to-date with developments in these areas, please sign up to our email list by adding your address below.